BBA
ALXN

Baker Bros. Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Baker Bros. Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,993,312
Closed -$611M – 134
2021
Q1 		$611M Sell
3,993,312
-4,767,482
-54% -$737M 2.65% 6
2020
Q4 		$1.37B Hold
8,760,794
– – 5.16% 6
2020
Q3 		$1B Hold
8,760,794
– – 4.01% 5
2020
Q2 		$983M Hold
8,760,794
– – 4.34% 5
2020
Q1 		$787M Buy
8,760,794
+502,726
+6% +$49.3M 4.84% 5
2019
Q4 		$893M Hold
8,258,068
– – 4.75% 5
2019
Q3 		$809M Hold
8,258,068
– – 5.5% 5
2019
Q2 		$1.08B Sell
8,258,068
-300,000
-4% -$38.7M 7.35% 4
2019
Q1 		$1.16B Buy
8,558,068
+2,174
+0% +$270K 7.41% 4
2018
Q4 		$833M Hold
8,555,894
– – 6.82% 4
2018
Q3 		$1.19B Hold
8,555,894
– – 7.83% 4
2018
Q2 		$1.06B Hold
8,555,894
– – 7.98% 4
2018
Q1 		$954M Buy
8,555,894
+2,030
+0% +$243K 8.08% 4
2017
Q4 		$1.02B Hold
8,553,864
– – 8.87% 3
2017
Q3 		$1.2B Hold
8,553,864
– – 9.73% 3
2017
Q2 		$1.04B Buy
8,553,864
+2,009,734
+31% +$234M 9.1% 3
2017
Q1 		$793M Buy
6,544,130
+835
+0% +$108K 6.49% 4
2016
Q4 		$801M Hold
6,543,295
– – 7.85% 3
2016
Q3 		$802M Hold
6,543,295
– – 7.28% 5
2016
Q2 		$764M Buy
6,543,295
+696
+0% +$98.8K 8.01% 5
2016
Q1 		$911M Hold
6,542,599
– – 9.61% 3
2015
Q4 		$1.25B Hold
6,542,599
– – 10.34% 3
2015
Q3 		$1.02B Hold
6,542,599
– – 9.45% 3
2015
Q2 		$1.18B Buy
+6,542,599
New +$1.13B 10.37% 3

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Baker Bros. Advisors's ALXN Position: Q2 2021 in Review

Baker Bros. Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 3,993,312 shares — an estimated $611M sold.

Baker Bros. Advisors first reported a position in ALXN in Q2 2015 and held it in 24 quarters. The position peaked at $1.37B in Q4 2020. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Baker Bros. Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Baker Bros. Advisors sold 3,993,312 Alexion Pharmaceuticals shares in Q2 2021, an estimated $611M.
  • Baker Bros. Advisors first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 24 quarters.
  • Baker Bros. Advisors's Alexion Pharmaceuticals position peaked at $1.37B in Q4 2020.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Baker Bros. Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.